Prosecution Insights
Last updated: November 04, 2026
Application No. 18/974,982

Preparations of Basic pH Hydrotropes & Methods for Making Same

Non-Final OA §102§103§112
Filed
Dec 10, 2024
Priority
Dec 11, 2023 — provisional 63/608,378
Examiner
VISHNYAKOVA, ELENA VLADIMIROVNA
Art Unit
Tech Center
Assignee
Aurora Pharmaceutical Inc.
OA Round
1 (Non-Final)
68%
Grant Probability
Favorable
1-2
OA Rounds
1y 1m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 68% — above average
68%
Career Allowance Rate
28 granted / 41 resolved
+8.3% vs TC avg
Strong +47% interview lift
Without
With
+46.6%
Interview Lift
resolved cases with interview
Typical timeline
3y 0m
Avg Prosecution
40 currently pending
Career history
79
Total Applications
across all art units

Statute-Specific Performance

§101
1.1%
-38.9% vs TC avg
§103
41.9%
+1.9% vs TC avg
§102
14.3%
-25.7% vs TC avg
§112
21.9%
-18.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 41 resolved cases

Office Action

§102 §103 §112
DETAILED ACTION This office action is in response to applicant’s filing dated December 10, 2024. Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of claims Claims 1 - 21 are pending in the instant application. Priority The present application was filed on December 10, 2024, and claims the benefits of priority to U.S. Provisional Application No. 63/608,378, filed on December 11, 2023. Claim Rejections - 35 USC § 112 Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 13 and 14 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claims 13 and 14 recite the term:”[…] “preferably” , (line 1) which is equivalent to phrase “such as”, renders the claim indefinite because it is unclear whether the limitations following the phrase are part of the claimed invention. See MPEP § 2173.05(d). Claim Rejections - 35 USC § 112(d) The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claim 2 is rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claim 2 is dependent on claim 1 and recites: “[…]wherein the hydrophobic polyaromatic organic compound is further defined as an organic compound containing nitrogen”. However, claim 1 recites: “[…]the hydrophobic polyaromatic compound contains at least two aromatic groups connected by a chain containing either a single secondary amine, a single amide, a single pyrazole, a single amino sulfone, or a single amino sulfone group attached to a single amide group”. Thus, claim 1 already recites functional groups (single secondary amine, a single amide, a single pyrazole, a single amino sulfone, or a single amino sulfone group attached to a single amide group) containing nitrogen, thereby making claim 2 an improper dependent claim for failing further limit independent claim 1. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 1 – 4, 8 – 10 and 13 – 17 are rejected under 35 U.S.C. 102(a)(1) and 102(a)(2) as being anticipated by Syed Akhtar et al (WO 2023/073513 A1, hereinafter Syed Akhtar). Instant claims are drawn to a basic pH (between 7 and 12; between 8 and 10.5) hydrotrope pharmaceutical preparation of a hydrophobic polyaromatic compound mixed with meglumine, wherein the meglumine is present in at least a 2:1 molar ratio of meglumine to polyaromatic compound, and wherein the hydrophobic polyaromatic compound contains at least two aromatic groups connected by a chain containing either a single secondary amine, a single amide, a single pyrazole, a single amino sulfone, or a single amino sulfone group attached to a single amide group, such as meloxicam. Said pharmaceutical preparation further comprises a wetting agent (e.g. polyethylene glycol, sucrose esters, sodium lauryl sulfate), suspending agent (e.g. sodium carboxymethylcellulose, guar gum, sodium alginate), viscosity-increasing agent (e.g. guar gum, sodium alginate) and viscosity-reducing agent (e.g. ethanol, isopropyl alcohol, methanol). Syed Akhtar teaches a pharmaceutical composition comprising meloxicam, rizatriptan benzoate, one or more pharmaceutically acceptable basifying agent (meglumine), one or more pharmaceutically acceptable polymer (e.g. polyethylene glycol), one or more pharmaceutically acceptable buffering agent, one or more pharmaceutically acceptable diluent, one or more pharmaceutically acceptable disintegrant (sodium alginate, guar gum, sodium carboxymethylcellulose), one or more pharmaceutically acceptable lubricant (sucrose stearate), surfactant (sodium lauryl sulphate), organic solvent (e.g. isopropyl alcohol, ethanol, methanol) (page 8, 3rd paragraph, page 15, Table 1). Syed Akhtar studies the solubility of meloxicam in water in presence of meglumine, where 20 mg of meloxicam + 25 mg of meglumine added to water, giving a solution with pH = 10.24 or pH =10.15 (page 16, Example 3, Table 3). Converting masses of meloxicam (20 mg) and meglumine (25 mg) into moles gives ~ 0.0569 mmol of meloxicam and ~ 0.128 mmol of meglumine, which constitutes the molar ratio meloxicam:meglumine 1:2.25. The molar ratio taught by Syed Akhtar falls within the claimed range “at least a 2:1 molar ratio of meglumine to meloxicam”. The pH of solution of meloxicam in presence of meglumine taught by Syed Akhtar is also within the instantly claimed ranges. MPEP 2131.03 states: "If the prior art discloses a point within the claimed range, the prior art anticipates the claim." UCB, Inc. v. Actavis Labs. UT, Inc., 65 F.4th 679, 687, 2023 USPQ2d 448 (Fed. Cir. 2023). Regarding limitations of claims 13 and 14, reciting “wherein an excess of meglumine beyond the 2:1 molar ratio acts as a buffer”, Syed Akhtar teaches the composition where solution of meloxicam and meglumine in water is present in the molar ratio meloxicam:meglumine 1:2.25. Thus, since prior art teaches the same composition, where the components are present in the same ratio, the excess of one component (meglumine) beyond the 2:1 molar ratio inherently acts as a buffer, because a compound and its properties are inseparable. As noted in MPEP 2112: a reference anticipates a claimed invention if the physical structure is identical, regardless of whether the reference explicitly teaches every inherent property. "Products of identical chemical composition cannot have mutually exclusive properties." In re Spada, 911 F.2d 705, 709, 15 USPQ2d 1655, 1658 (Fed. Cir. 1990). Thus, Syed Akhtar discloses the same pharmaceutical composition, wherein the same components are present in the same amounts, and exhibit the same properties such as pH. Therefore, the teachings of prior art anticipate the claimed pharmaceutical preparation. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1, 5, 6, 11 and 12, 18 – 21 are rejected under 35 U.S.C. 103 as being unpatentable over Syed Akhtar et al (WO 2023/073513 A1) in view of Hsu et al (WO 2005/037157 A1, hereinafter Hsu) and PubChem (Amoxicillin | C16H19N3O5S | CID 33613, hereinafter PubChem). Instant claims are drawn to a basic pH (between 9 and 10) hydrotrope pharmaceutical preparation of a hydrophobic polyaromatic compound (meloxicam) mixed with meglumine, wherein the meglumine is present in at least a 2:1 molar ratio of meglumine to polyaromatic compound, and wherein the hydrophobic polyaromatic compound is present at about 0.01% to 45 % weight per volume, about 0.025% to 40% weight per volume, 0.05% to 33.3% weight per volume. Said pharmaceutical preparation further comprises a preservative (e.g. benzyl alcohol), an antioxidant (e.g. vitamin E) and a pharmaceutical active ingredient, such as amoxicillin, in suspension or solution. Syed Akhtar teaches a pharmaceutical composition comprising meloxicam, rizatriptan benzoate, one or more pharmaceutically acceptable basifying agent (meglumine), and excipients such as one or more of polymers, buffering agents, disintegrants, binders, surfactants, fillers, and lubricants. Syed Akhtar teaches the composition, where the solution of meloxicam and meglumine in water has a molar ratio meloxicam:meglumine 1:2.25 and pH = 10.24 or pH =10.15. Syed Akhtar does not teach the composition, where the pH is between 9 and 10, or where the composition comprises preservatives, antioxidants or antibiotics (e.g. amoxicillin). Syed Akhtar does not teach the composition where the hydrophobic polyaromatic compound is present at about 0.01% to 45% weight per volume, about 0.025% to 40% weight per volume or 0.05% to 33.3% weight per volume. However, Hsu teaches a pharmaceutical formulation to be applied to the body surface and provide transdermal administration of a hydrophilic drug. The formulation comprises: (a) a therapeutically effective amount of the drug (e.g. meloxicam or diclofenac); (b) an effective flux-enhancing amount of a basic permeation enhancer composition containing an inorganic hydroxide and a nitrogenous base (e.g. meglumine); and (c) a pharmaceutically acceptable carrier suitable for transdermal drug administration (page 3, [0011]-[0014]). The formulation itself has a pH in the in the range of about 8.0 to about 13.0, preferably about 8.5 to about 11.5, more preferably about 9.5 to about 11.5 (page 9, [0038]). The pH of formulations taught by Hsu, fall within or overlap with the instantly claimed pH. The term “hydrophilic drugs” for transdermal administration is defined by Hsu as drugs that have an apparent aqueous solubility greater than 2.5 mg/ml at a pH of 8.0 when measured at 25°C (page 10. [0040]). Hsu further teaches a delivery system for transdermally administering a hydrophilic drug, which system is comprising: at least one drug reservoir containing (i) a therapeutically effective amount of the hydrophilic drug (e.g. analgesic agents, antiinflammatory agents or antibiotics) and (ii) an effective flux-enhancing amount of a basic permeation enhancer composition containing an inorganic hydroxide and a weaker nitrogenous base (e.g. meglumine). The formulation or drug reservoir may be aqueous (page 13, [0051]). Various additives such as antioxidants (e.g. α-tocopherol) or preservatives (e.g. sodium benzoate) may be included in the topical formulations (page 15, [0060]-[0061]). Hsu studies the in vitro permeation of meloxicam from formulations A, B, C, and D, where the formulation B contains 0.35 g of meloxicam, 0.7 g of hexylene glycol, 0.35 g of meglumine, 0.50 g of glycerin, 0.305 g of DI water and 0.055 g of NaOH (pages 19 – 20, Example 1, Table 1). Calculating the total volume of formulation B taught by Hsu from given masses and known densities of liquid components, the volume of the formulation will be approximately 1.95mL, so calculated % weight per volume of meloxicam in the formulation B will be ~17.9%. The calculated % weight per volume of meloxicam in the formulation B falls within the claimed ranges. MPEP 2144.05 states: In the case where the claimed ranges "overlap or lie inside ranges disclosed by the prior art" a prima facie case of obviousness exists. In re Wertheim, 541 F.2d 257, 191 USPQ 90 (CCPA 1976); In re Woodruff, 919 F.2d 1575, 16 USPQ2d 1934 (Fed. Cir. 1990) (The prior art taught carbon monoxide concentrations of "about 1-5%" while the claim was limited to "more than 5%." The court held that "about 1-5%" allowed for concentrations slightly above 5% thus the ranges overlapped.). Regarding limitations of claims 11 and 12, which recite the pharmaceutical preparation further comprising a pharmaceutical active ingredient, such as amoxicillin, in suspension or solution, Hsu teaches formulations, where the formulation is aqueous, where the drug is antibiotic and where the drug delivery system comprises at least one drug reservoir. According to PubChem, amoxicillin is an antibiotic that has a low water solubility. Thus, in aqueous formulations taught by Hsu amoxicillin is present as suspension or solution (depending on concentration). Thus, since Syed Akhtar teaches pharmaceutical compositions comprising the same active agents and excipients, taken the same molar ratio and maintaining the same or similar pH value as claimed pharmaceutical preparation, and since Hsu teaches structurally similar formulations comprising the same ingredients, where the % weight/volume concentration of the active agents falls within the claimed ranges and the pH value remains the same, and where Hsu recites some additional excipients or active agents, it would have been prima facie obvious to one of ordinary skill in the art before the effective filing date of the present invention to modify the formulations of Syed Akhtar by varying excipients, additional active agents or weight percentages of ingredients while maintaining the critical parameters (molar ratio and pH) to arrive at claimed pharmaceutical preparations. The one of ordinary skills would be motivated to do so to optimize the formulation content and component concentrations without disrupting the core compositions with the reasonable expectation of success. Claims 1 and 7 are rejected under 35 U.S.C. 103 as being unpatentable over Syed Akhtar et al (WO 2023/073513 A1) in view of Kalra et al (IN201911048645 A, hereinafter Kalra). Instant claims are drawn to a basic pH hydrotrope pharmaceutical preparation of a hydrophobic polyaromatic compound (meloxicam) mixed with meglumine, wherein the meglumine is present in at least a 2:1 molar ratio of meglumine to polyaromatic compound. Said pharmaceutical preparation further comprises a palatability enhancer. Syed Akhtar teaches a pharmaceutical composition comprising meloxicam, rizatriptan benzoate, one or more pharmaceutically acceptable basifying agent (meglumine), and excipients such as maltodextrin (page 11, 1st paragraph). Syed Akhtar teaches the composition, where the solution of meloxicam and meglumine in water has a molar ratio meloxicam:meglumine 1:2.25 and pH = 10.24 or pH =10.15. Kalra teaches orally dispersible taste-masked formulations of bitter drugs, wherein the formulation comprises of a ternary complex of the bitter drug, such as meloxicam, meglumine and maltodextrin. Kalra teaches maltodextrin as a palatability enhancing agent (page 20, “Palatability study”). Thus, since Syed Akhtar teaches pharmaceutical compositions comprising the same active agents and excipients, taken the same molar ratio and maintaining the same or similar pH value as claimed pharmaceutical preparation, where said pharmaceutical compositions are suitable for oral administration, and since Kalra teaches orally dispersible taste-masked formulations comprising meloxicam, meglumine and maltodextrin , where maltodextrin is added as a palatability enhancer, it would have been prima facie obvious to one of ordinary skill in the art before the effective filing date of the present invention to modify the formulations of Syed Akhtar by adding maltodextrin to mask bitter taste of oral formulation of meloxicam to arrive at claimed pharmaceutical preparations with the reasonable expectation of success. Especially since prior art teaches that maltodextrin is effectively masking the bitter taste of similar pharmaceutical formulations. Therefore, taking all together, taught by prior art, the invention as a whole is prima facie obvious to one of ordinary skill in the art at the time the invention was made, as evidenced by the references, especially in the absence of evidence to the contrary. Conclusion Claims 1 – 21 are rejected. No claim is allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to ELENA V VISHNYAKOVA whose telephone number is (571)272-3781. The examiner can normally be reached 7:30am - 5pm ET. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, RENEE CLAYTOR can be reached at (571)272-8394. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /E.V.V./Examiner, Art Unit 1691 /SAVITHA M RAO/Primary Examiner, Art Unit 1691
Read full office action

Prosecution Timeline

Dec 10, 2024
Application Filed
Oct 07, 2026
Non-Final Rejection mailed — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12780832
HETEROCYCLIC COMPOUND ACTING ON G12D MUTANT KRAS PROTEIN
2y 8m to grant Granted Nov 03, 2026
Patent 12758540
COMPOUND FOR PREVENTING OR TREATING A VIRAL INFECTION
3y 11m to grant Granted Oct 13, 2026
Patent 12760018
BICYCLIC COMPOUNDS
3y 5m to grant Granted Oct 13, 2026
Patent 12723039
SMALL MOLECULE INHIBITORS OF SLC15A4 WITH ANTI-INFLAMMATORY ACTIVITY
4y 0m to grant Granted Sep 01, 2026
Patent 12691103
APPLICATION OF RILUZOLE IN TREATMENT OF OLIGOSPERMIA
2y 11m to grant Granted Jul 28, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
68%
Grant Probability
99%
With Interview (+46.6%)
3y 0m (~1y 1m remaining)
Median Time to Grant
Low
PTA Risk
Based on 41 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month